All AbMole products are for research use only, cannot be used for human consumption.
ZSTK474 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, which strongly inhibits cancer cell proliferation. Phosphoinositide 3-kinase (PI3K) is a potential target in cancer therapy. Inhibition of PI3K is believed to induce apoptosis. ZSTK474 effectively inhibited the growth of human cancer xenografts in vivo. ZSTK474 treatment suppressed the expression of nuclear cyclin D1 and Ki67 and also the expression of phospho-Akt, both of which are hallmarks of proliferation. We demonstrate that ZSTK474 induces G1arrest along with tumour suppression. Moreover, ZSTK474 suppresses the tumour growth without inducing apoptosis. Interestingly, long-term (3-month) administration of ZSTK474 maintained such increase in G1 cells and tumour suppression. ZSTK474 exerts its in vivo antitumour efficacy via G1 arrest but not via apoptosis as long as it is administered.
| Cell Experiment | |
|---|---|
| Cell lines | panel of 39 human cancer cell lines |
| Preparation method | Analysis of Cell Proliferation Inhibition The inhibition of cell proliferation was assessed by measuring changes in total cellular protein in a culture of each cell line in the JFCR panel of cell lines after 48 hours of drug treatment by use of a sulforhodamine B assay. The 50% growth inhibition (GI 50 ) value of the drug was calculated as described previously. The graphic representation of a drug’s mean differential growth inhibition for the cell line panel was based on a calcula-tion that used a set of GI 50 values, as described previously. To analyze the correlation between the mean graphs of drug A and drug B, the COMPARE computer algorithm was developed as previously described by Paull et al. The Pearson correla-tion coeffi cient between the mean graphs of drug A and drug B was calculated (n = 39). |
| Concentrations | 0~10μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Human A549 lung cancer cells, PC-3 prostate cancer cells, and WiDr colon cancer cells tumor xenografts |
| Formulation | 5% hydroxypropylcellulose in water |
| Dosages | 100, 200, or 400 mg/kg daily from days 0 to 13 |
| Administration | orally |
| Molecular Weight | 417.41 |
| Formula | C19H21F2N7O2 |
| CAS Number | 475110-96-4 |
| Solubility (25°C) | DMSO 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PI3K Products |
|---|
| PI3Kγ inhibitor AZ2
PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3). |
| NIBR-17
NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth. |
| RV-1729
RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ). |
| Vulolisib
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. |
| Vps34-IN-4
Vps34-IN-4 is a potent, selective, and orally active inhibitor of VPS34. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
